BY CHRISTOPHER DUE KARLSSON
-
Novo Nordisk seeks million-dollar damages following failed acquisition
A frustrating stage 3 research study in 2014 motivated Novo Nordisk to go down the high blood pressure prospect ocedurenone.
-
Bioarctic receives EUR 10m from Eisai sales of Alzheimer’s drug
The landmark settlement originates from sales of the Alzheimer’s medication Leqembi.
-
Sanofi’s eczema drug accepted for FDA priority review
The sped up evaluation is offered to the gold egg Dupixent as a therapy for the skin illness bullous pemphigoid.
-
Zealand sees disappointing Novo study as advantage: “Most patients are not looking for the biggest weight loss”
In line with Zealand Pharma CEO Adam Steensberg, Novo Nordisk’s cagrisema examine validates the corporate’s potential place within the weight-loss market.
-
Morgan Stanley forecasts Novo Nordisk’s US weight-loss market share shrinking
The financial institution approximates that Novo Nordisk’s share of the United States weight-loss market will certainly be 20% in 10 years.
-
FDA approves Roche’s first tablet against genetic neuromuscular disorder
The brand-new tablet computer can either be ingested entire or liquified in water, according to the Swiss pharmaceutical firm.
-
Novo Nordisk seeks million-dollar damages following failed acquisition
A disappointing phase 3 study last year prompted Novo Nordisk to drop the blood pressure candidate ocedurenone.
-
Catalent appoints new board members
The United States agreement maker was obtained by Novo Holdings in 2015 in the biggest company handle Danish background.
-
Morgan Stanley forecasts Novo Nordisk’s US weight-loss market share shrinking
The bank estimates that Novo Nordisk’s share of the US weight-loss market will be 20% in ten years.
-
Bioarctic receives EUR 10m from Eisai sales of Alzheimer’s drug
The milestone payment comes from sales of the Alzheimer’s drug Leqembi.
